

Press Release

Reorganization of the Research and Development Structure

Tokyo, Japan (August 7, 2023) - Daiichi Sankyo (TSE: 4568) today announced that it has decided to close its Japanese research and development (R&D) subsidiary, Daiichi Sankyo RD Novare Co., Ltd. (headquartered in Edogawa-ku, Tokyo; hereinafter called “RD Novare”). Daiichi Sankyo will absorb RD Novare's functions into its own organization further to strengthen its R&D capabilities.

RD Novare (approx. 400 employees) was founded as Daiichi Sankyo RD Associe Co., Ltd. in 2006 to support Daiichi Sankyo’s drug discovery and clinical development. In 2011, the company name was changed to the current one. RD Novare, which has a cutting-edge research technology infrastructure and a strong clinical development capability, plays a role in the Daiichi Sankyo group of companies’ R&D by contributing to the creation of innovative pharmaceuticals. RD Novare will conclude its business as a corporate entity on March 31, 2024.

With this reorganization to further enhance the productivity of its R&D, Daiichi Sankyo will merge R&D strengths within the Daiichi Sankyo group of companies, leading to the construction and implementation of a consistent research strategy for drug discovery, rapid decision-making, and the strengthening of global clinical development for the 5DXd-ADCs, including ENHERTU®.

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit <http://www.daiichisankyo.com/>.

Media Contacts:

Japan:

Koji Ogiwara
Daiichi Sankyo Co., Ltd.
ogiwara.koji.ay@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations Contact:

DaiichiSankyoIR@daiichisankyo.co.jp